PMID- 35606777
OWN - NLM
STAT- MEDLINE
DCOM- 20220525
LR  - 20220716
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 22
IP  - 1
DP  - 2022 May 23
TI  - Serum creatinine/cystatin C ratio is a surrogate marker for sarcopenia in 
      patients with idiopathic pulmonary fibrosis.
PG  - 203
LID - 10.1186/s12890-022-02000-3 [doi]
LID - 203
AB  - BACKGROUND: The serum creatinine/cystatin C (Cr/CysC) ratio has attracted 
      attention as a marker for sarcopenia, but has not been studied in patients with 
      idiopathic pulmonary fibrosis (IPF). This study aimed to confirm the utility of 
      the serum Cr/CysC ratio in predicting sarcopenia and investigate its clinical 
      relevance. METHODS: This cross-sectional pilot study prospectively enrolled 
      patients with stable IPF. IPF was diagnosed through multidisciplinary discussions 
      according to the 2018 international guidelines, and sarcopenia was diagnosed 
      according to the 2019 consensus report of the Asian Working Group for Sarcopenia. 
      Patient-reported outcomes (PROs) were evaluated using the modified Medical 
      Research Council (mMRC) dyspnea scale, chronic obstructive pulmonary disease 
      assessment test (CAT), and King's Brief Interstitial Lung Disease (K-BILD) 
      questionnaire. The associations between serum Cr/CysC ratio and the presence of 
      sarcopenia and other clinical parameters, including PROs scores, were examined. 
      RESULTS: The study enrolled 49 Japanese patients with IPF with a mean age of 
      73.0 +/- 7.7 years and a mean percentage of predicted forced vital capacity of 
      80.4 +/- 15.5%. Sarcopenia was diagnosed in 18 patients (36.7%), and the serum 
      Cr/CysC ratio was 0.86 [0.76-0.94] (median [interquartile range]). The receiver 
      operating characteristic curve analyses for the detection of sarcopenia according 
      to the serum Cr/CysC showed that the area under the curve, optimal cutoff value, 
      specificity, and sensitivity were 0.85, 0.88, 0.65, and 0.94, respectively. 
      Sarcopenia was identified in 13% of patients with a high serum Cr/CysC ratio 
      (>/= 0.88) and 60% of patients with a low serum Cr/CysC ratio (< 0.88) (P < 0.001). 
      Multiple linear regression analysis showed that the serum Cr/CysC ratio was an 
      independent predictive marker of worse PROs evaluated using mMRC (P < 0.05), CAT 
      (P < 0.05), and K-BILD (P < 0.05). CONCLUSIONS: This study showed that the serum 
      Cr/CysC ratio may be a surrogate marker of sarcopenia in patients with IPF. 
      Furthermore, it is important to pay attention to the serum Cr/CysC ratio because 
      a lower serum Cr/CysC ratio is associated with worse PROs. Further studies are 
      required to validate these observations to determine whether the Cr/CysC ratio 
      can be used to detect sarcopenia in patients with IPF.
CI  - (c) 2022. The Author(s).
FAU - Fujita, Kohei
AU  - Fujita K
AD  - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City 
      University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, 
      Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
FAU - Ohkubo, Hirotsugu
AU  - Ohkubo H
AD  - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City 
      University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, 
      Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. hohkubo@med.nagoya-cu.ac.jp.
FAU - Nakano, Akiko
AU  - Nakano A
AD  - Department of Respiratory Medicine, Nagoya City University East Medical Center, 
      Nagoya, Japan.
FAU - Takeda, Norihisa
AU  - Takeda N
AD  - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City 
      University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, 
      Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
FAU - Fukumitsu, Kensuke
AU  - Fukumitsu K
AD  - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City 
      University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, 
      Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
FAU - Fukuda, Satoshi
AU  - Fukuda S
AD  - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City 
      University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, 
      Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
FAU - Kanemitsu, Yoshihiro
AU  - Kanemitsu Y
AD  - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City 
      University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, 
      Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
FAU - Uemura, Takehiro
AU  - Uemura T
AD  - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City 
      University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, 
      Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
FAU - Tajiri, Tomoko
AU  - Tajiri T
AD  - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City 
      University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, 
      Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
FAU - Maeno, Ken
AU  - Maeno K
AD  - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City 
      University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, 
      Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
FAU - Ito, Yutaka
AU  - Ito Y
AD  - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City 
      University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, 
      Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
FAU - Oguri, Tetsuya
AU  - Oguri T
AD  - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City 
      University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, 
      Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
FAU - Ozawa, Yoshiyuki
AU  - Ozawa Y
AD  - Department of Radiology, Nagoya City University Graduate School of Medical 
      Sciences, Nagoya, Japan.
FAU - Murase, Takayuki
AU  - Murase T
AD  - Department of Pathology and Molecular Diagnostics, Graduate School of Medical 
      Sciences, Nagoya City University, Nagoya, Japan.
FAU - Niimi, Akio
AU  - Niimi A
AD  - Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City 
      University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, 
      Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220523
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
RN  - 0 (Biomarkers)
RN  - 0 (Cystatin C)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Biomarkers/blood
MH  - Creatinine/blood
MH  - Cross-Sectional Studies
MH  - Cystatin C/blood
MH  - Humans
MH  - *Idiopathic Pulmonary Fibrosis/complications/diagnosis
MH  - Pilot Projects
MH  - *Sarcopenia/diagnosis
PMC - PMC9128295
OTO - NOTNLM
OT  - Bioelectrical impedance
OT  - Creatinine
OT  - Cystatin C
OT  - Idiopathic pulmonary fibrosis
OT  - Patient-reported outcomes
OT  - Sarcopenia
COIS- The authors declare that they have no competing interest.
EDAT- 2022/05/24 06:00
MHDA- 2022/05/26 06:00
PMCR- 2022/05/23
CRDT- 2022/05/23 23:48
PHST- 2022/02/12 00:00 [received]
PHST- 2022/05/13 00:00 [accepted]
PHST- 2022/05/23 23:48 [entrez]
PHST- 2022/05/24 06:00 [pubmed]
PHST- 2022/05/26 06:00 [medline]
PHST- 2022/05/23 00:00 [pmc-release]
AID - 10.1186/s12890-022-02000-3 [pii]
AID - 2000 [pii]
AID - 10.1186/s12890-022-02000-3 [doi]
PST - epublish
SO  - BMC Pulm Med. 2022 May 23;22(1):203. doi: 10.1186/s12890-022-02000-3.